CARTESIAN study: INSERM coordinates an international collaboration aimed at identifying long-term cardiovascular consequences of COVID-19

Étude CARTESIAN : l’INSERM coordonne une collaboration internationale sur les conséquences cardiovasculaires long-terme du COVID-19

COVID-19 is emerging as a novel factor accelerating cardiovascular aging. Many scientists have highlighted the role of COVID-19-induced endothelial dysfunction in pathophysiology of the disease. The CV system is extensively affected by COVID-19 and long-term consequences on the cardiovascular system have been shown, including myocardial fibrosis. A parallel phenomenon of vascular fibrosis and stiffening is thus plausible and may pose COVID-19 survivors at increased risk of future CV events.

For this reason, in May 2020 an international collaboration was launched, aimed at identifying long-term cardiovascular consequences of COVID-19 infection on non-invasive biomarkers of early vascular ageing, supported by the ARTERY (Association for Research into Arterial Structure and Physiology) Society and the COST (European Cooperation in Science and Technology) Action CA18216 VascAgeNet. This international collaboration is coordinated by Rosa Maria BRUNO and Pierre BOUTOUYRIE (Team 7 PARCC-INSERM) and involves to date 52 centres from 25 countries in 5 continents.

In all centres, arterial stiffness and central haemodynamics are evaluated 6 and 12 months after COVID-19 infection, in order to investigate whether COVID-19 induces accelerated vascular aging.

In France, the study includes an in-depth evaluation of myocardial function at rest and during exercise testing (under the scientific responsibility of Jean-Sebastien Hulot – Team 7 leader PARCC INSERM), and received funding support from APHP-HEGP (Appel d’offre Mecenat).

In order to fund the CARTESIAN study at an international level, a fundraising campaign has just being launched. %100 of the collected funds will go to long term follow-up of this unique cohort. 

Below the link to donate: